Evidence map›Paper›PMID 23014672›Full record

ArticleIntegrative biology : quantitative biosciences from nano to macro2013

Development of siRNA-probes for studying intracellular trafficking of siRNA nanoparticles.

Christopher A Alabi, Gaurav Sahay, Robert Langer, Daniel G Anderson

Abstract read
In one paragraph

Article in Integrative biology : quantitative biosciences from nano to macro, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex.Nanomedicine : nanotechnology, biology, and medicine · 2016
    Article
  9. Nanoparticles and their applications in cell and molecular biology.Integrative biology : quantitative biosciences from nano to macro · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christopher A AlabiDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA 02142, USA.
Gaurav Sahay
Robert Langer
Daniel G Anderson

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
Targeted Nanoparticle DNA Therapy for Ovarian CancerR01CA132091 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI SAWICKI, JANET A · 2008 to 2012
$1.4M
Targeting Nanoparticle DNA Delivery to Prostate TumorsR01CA115527 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI SAWICKI, JANET A · 2007 to 2010
$1.3M
NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA115527NCI NIH HHS R01-CA115527NCI NIH HHS R01 CA132091NCI NIH HHS R01-CA132091NIBIB NIH HHS R37 EB000244NIBIB NIH HHS R37-EB000244
6 · The paper itself

Abstract

One important barrier facing the delivery of short interfering RNAs (siRNAs) via synthetic nanoparticles is the rate of nanoparticle disassembly. However, our ability to optimize the release kinetics of siRNAs from nanoparticles for maximum efficacy is limited by the lack of methods to track their intracellular disassembly. Towards this end, we describe the design of two different siRNA-based fluorescent probes whose fluorescence emission changes in response to the assembly state of the nanoparticle. The first probe design involves a redox-sensitive fluorescence-quenched probe that fluoresces only when the nanoparticle is disassembled in a reductive environment. The second probe design is based on a FRET-labeled siRNA pair that fluoresces due to the proximity of the siRNA pair when the nanoparticle is intact. In both approaches, the delivery vehicle need not be labeled. The utility of these probes was investigated with a lipidoid nanoparticle (LNP) as proof-of-concept in both extracellular and intracellular environments. Fluorescence kinetic data from both probes were fit to a two-phase release and decay curve and subsequently quantified to give intracellular disassembly rate constants. Quantitative analysis revealed that the rate constant of siRNA release measured via the fluorescence-quenched probe was almost identical to the rate constant for nanoparticle disassembly measured via the FRET-labeled probes. Furthermore, these probes were utilized to determine subcellular localization of LNPs with the use of automated high-resolution microscopy as they undergo dissociation. Interestingly, this work shows that large amounts of siRNA remain inside vesicular compartments. Altogether, we have developed new siRNA probes that can be utilized with multiple nanocarriers for quantitative and qualitative analysis of nanoparticle dissociation that may serve as a design tool for future delivery systems.

Indexed as

Molecular Probe TechniquesNanoparticlesHeLa CellsHumansMicroscopy, FluorescenceMolecular ImagingMolecular ProbesRNA, Small InterferingMolecular ProbesRNA, Small Interfering

Identifiers

PMID23014672
PMCPMC3524365

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.